Figure 7 | British Journal of Cancer

Figure 7

From: Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01

Figure 7

(A) Profound enhancement of apoptosis by the combinations of VA (1.0 or 5.0 mM) with CC, STP, UCN-01 or Parthenolide in the representative cultured thoracic cancer cells TE12 or H211. Apoptosis was quantified by TUNEL-based ApoBrdU assay and flow cytometry. (B) Summary of the VA dose-dependent additive or supra-additive induction of apoptosis in the panel of six cultured thoracic cancer cells treated with VA and UCN-01 (500 nM) combinations. Additive enhancement of apoptosis was observed in H460 and H513 cells treated with VA (1.0 mM+UCN-01; *P>0.05 combination effects vs sum of individual drug effects) and supra-additive enhancement of apoptosis was observed in other cell lines and combinations, especially at the clinically relevant concentration of VA of 1.0 mM (# P<0.05–0.001 combination effects vs sum of individual drug effects). The magnitude of apoptosis induced by VA+UCN-01 was clearly dependent on VA concentrations (+P<0.05–0.001 VA(1.0)+UCN-01 vs VA(5 mM)+UCN-01). Data are expressed as mean±s.e.m. of three independent experiments.

Back to article page